drugset / Trial / NCT05985655
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Timeline
- Start
- 2023-07-06
- Primary completion
- 2028-01
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GTAEXS617 | Unknown | — | Oral |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Fulvestrant | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |